LABORATORY ASSESSMENT OF A SYSTEMIC ANTIMYCOTIC MICONAZOLE (BASE): IN VIVO ACTIVITY

Abstract

Therapeutic efficacy of miconazole (base) administered parenterally was tested in the model of disseminated candidiasis in mice. Seven miconazole intravenous doses of 12.5 to 50mg/kg/day once or twice daily in C.albicans-infected mice significantly increased the survival rate compared with a placebo injection during the two-weeks postinfection observation period. Sufficiently favorable results were also obtained when intravenous administration was delayed for 24 hours after infection. Comparable with the increase of the survival rate, colony counts from the kidney of miconazole-treated mice were markedly reduced compared with those of untreated controls. After intravenous injection of 50mg/kg of miconazole in normal mice, the serum concentration of 30μg/ml was occurred after 15 minutes, thereafter decreasing rapidly.